<DOC>
	<DOCNO>NCT00684385</DOCNO>
	<brief_summary>The purpose study provide ZD1839 patient locally advance and/or metastatic non-operable non-small cell lung cancer ( stage III IV ) recurrent and/or metastatic squamous cell head neck cancer receive therapy expand access basis due inability meet eligibility criterion on-going recruiting trial , inability participate clinical trial ( e.g. , poor performance status , lack geographic proximity ) , medical intervention consider appropriate acceptable .</brief_summary>
	<brief_title>An Expanded Access Programme With Iressa Patients With Non-Small-Cell Lung Cancer Cancer Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Have receive least one course standard systemic chemotherapy radiation therapy Are ineligible chemotherapy radiotherapy Are ineligible candidate enrollment available ZD1839 trial NSCLC squamous cell H &amp; NC Are , investigator opinion , medically suitable chemotherapy . Current eligibility ( i.e. , meet inclusion exclusion criterion except sign informed consent ) ZD1839 protocol available patient , previous enrollment blind ZD1839 protocol Patients blind protocol may consider acceptance , AstraZeneca 's permission , trial completion unblinding patient . Patients eligible previously enrol openlabel unblinded ZD1839 clinical trial may consider acceptance AstraZeneca 's permission Incomplete heal prior oncologic major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>